PD-L1 immunohistochemistry assay concordance in urothelial carcinoma of the bladder and hypopharyngeal squamous cell carcinoma
A Hodgson, E Slodkowska, A Jungbluth… - The American journal …, 2018 - journals.lww.com
Abstract Programmed death ligand-1 (PD-L1) immunohistochemistry is used to guide
treatment decisions regarding the use of checkpoint immunotherapy in the management of
urothelial carcinoma of the bladder and hypopharyngeal (HP) squamous cell carcinoma.
With increasing PD-L1 testing options, a need has arisen to assess the analytical
comparability of diagnostic assays in order to develop a more sustainable testing strategy.
Using tissue microarrays, PD-L1 expression in tumor cells (TCs) and immune cells (ICs) was …
treatment decisions regarding the use of checkpoint immunotherapy in the management of
urothelial carcinoma of the bladder and hypopharyngeal (HP) squamous cell carcinoma.
With increasing PD-L1 testing options, a need has arisen to assess the analytical
comparability of diagnostic assays in order to develop a more sustainable testing strategy.
Using tissue microarrays, PD-L1 expression in tumor cells (TCs) and immune cells (ICs) was …
